Advertisement
-
-
Envisioning how to advance the MASH field
This Perspective discusses the nomenclature change from nonalcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease (MASLD) and proposes steps necessary to improve care and end the public health threat posed by MASLD and metabolic dysfunction-associated steatohepatitis.
-
-
MASLD/NAFLD
Fuelled by increasing obesity rates, metabolic dysfunction associated steatotic liver disease (MASLD, formerly known as NAFLD) has emerged as a leading global cause of chronic liver disease in the past few decades. Despite growing prevalence, the factors influencing MASLD development and subsequent progression to metabolic dysfunction associated steatohepatitis (MASH), liver fibrosis, cirrhosis and hepatocellular carcinoma are poorly understood. In this article series, Nature Reviews Gastroenterology & Hepatology explores the epidemiology of MASLD, disease mechanisms and therapeutics, and clinical approaches to diagnosis and management.
Trending - Altmetric
-
The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic
-
IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
-
Gastrointestinal and brain barriers: unlocking gates of communication across the microbiota–gut–brain axis
-
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice